| Name | Title | Contact Details |
|---|
Ophthonix, Inc. is a Vista, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Eurogentec North America, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Spero Health, Inc., is an integrated healthcare services organization specializing in local and affordable outpatient care for individuals suffering from substance use disorders with a mission to “Save Lives, Instill Hope, and Restore Relationships.” Spero Health utilizes an innovative evidenced-based integrated care model that combines both physical and behavioral healthcare services under one roof to treat the whole patient. This integrated care model combines physician services (including medication-assisted treatment), behavioral health counseling, recovery support services, medication management and patient and family education. Its community-based approach to treatment allows patients to continue working and caring for their families as they overcome addiction. Based in Nashville, Tenn. and privately held by Heritage Group, Health Velocity Capital, South Central, Inc. and Frist Cressey Ventures, Spero Health operates 23 freestanding outpatient clinics located throughout Kentucky, Ohio and Indiana. Providing care for more than 5,300 patients each month, Spero is one of the largest office-based opioid treatment providers in the country and is in network with Medicaid and most commercial insurance plans.
Augmedics develops xvision™ – an Augmented-Reality Head-Mounted Display for spine surgery. xvision allows surgeons to see the patient`s anatomy through skin and tissue, as if they had "X-Ray Vision". Based on Augmedics` patented technology, the xvision system can project the patient`s anatomy, in real time, directly onto the surgeon`s retina, with surgical precision and outstanding depth perception. xvision will increase safety in surgery, reduce x-ray radiation, and facilitate minimally invasive procedures.
Integrity Applications is dedicated to developing breakthrough innovations in non-invasive glucose monitoring devices. Since its founding in 2001, Integrity Applications has been committed to improving the quality of life for people with diabetes by removing the obstacles of traditional invasive devices, namely painful pricking of fingertips, added costs as a result of disposables, as well as inconvenience. Integrity Applications has developed a state-of-the-art way to measure glucose levels using three non-invasive technologies, ultrasound, thermal, and electromagnetic in combination with a proprietary algorithm to produce a weighted glucose measurement. After proof of concept in 2002, Integrity Applications developed the first working prototype, GlucoTrack in August 2003. GlucoTrack® Model DF-F received CE Mark approval in June 2013 and KFDA in March 2016. GlucoTrack is currently being marketed in the European Union and in South Korea.